Lupin Receives USFDA Tentative Approval for Apixaban Oral Suspension
Lupin has received tentative approval from the US Food and Drug Administration for its Apixaban Oral Suspension 1.25 mg/mL, an oral liquid formulation of apixaban used for anticoagulation therapy. This formulation offers an alternative for adults who have difficulty swallowing tablets. Upon final approval, Lupin plans to manufacture the product at its Somerset, New Jersey facility. CEO Vinita Gupta highlighted the approval as part of Lupin's focus on developing differentiated medicines addressing patient needs.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (61/100). Lens Score 40/100.
Outlets measured: businessstandard, news18, freepressjournal, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–65/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 28 Sept, 04:24 am. Other outlets followed.